| MDL | MFCD28142357 |
|---|---|
| Molecular Weight | 165.62 |
| Molecular Formula | C6H12ClNO2 |
| SMILES | C=CC(N)CCC(O)=O.Cl |
Vigabatrin hydrochloride (γ-Vinyl-GABA hydrochloride), a inhibitory neurotransmitter GABA vinyl-derivative, is an orally active and irreversible GABA transaminase inhibitor. Vigabatrin hydrochloride is an antiepileptic agent, which acts by increasing GABA levels in the brain by inhibiting the catabolism of GABA by GABA transaminase [1] [2] [3] .
A significant increase in seizure threshold is observed following systemic (i.p.) administration of high (600 or 1200 mg/kg) doses of Vigabatrin. Bilateral microinjection of Vigabatrin (10 μg) into either the anterior or posterior substantia nigra pars reticulata (SNr) also increased seizure threshold, but less markedly than systemic treatment. Focal delivery into the subthalamic nucleus (STN) increased seizure threshold more markedly than either intranigral or systemic administration of Vigabatrin [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Vigabatrin inhibits the uptake of taurine in Caco-2 and MDCK cells to 34% and 53%, respectively, at a concentration of 30 mM. In Caco-2 cells the uptake of Vigabatrin under neutral pH conditions is concentration-dependent and saturable with a Km-value of 27 mM. Vigabatrin is able to inhibit the uptake of taurine in intestinal and renal cell culture models [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT03003143 | Seoul National University Hospital |
Autoimmune Encephalopathy
|
November 2016 | Not Applicable |
| NCT04062890 | University of Arizona|Arizona Department of Health Services |
Hyperinsulinism|Insulin Resistance|Insulin Sensitivity|Glucose Intolerance|Hypertension
|
December 15, 2019 | Phase 2 |
| NCT04772547 | University of Florida|Yale University|Thomas Jefferson University|American Heart Association |
Status Epilepticus, Electrographic|Coma
|
September 22, 2021 | Phase 2 |
| NCT00527683 | NYU Langone Health|Catalyst Pharmaceuticals, Inc. |
Cocaine Dependence
|
April 2007 | Phase 2 |
| NCT00611130 | Catalyst Pharmaceuticals, Inc. |
Cocaine Dependence
|
January 2008 | Phase 2 |
| NCT04302116 | Kullasate Sakpichaisakul|Queen Sirikit National Institute of Child Health |
Infantile Spasm|West Syndrome
|
May 18, 2020 | Not Applicable |
| NCT01281202 | Catalyst Pharmaceuticals, Inc.|National Institute on Drug Abuse (NIDA)|VA Office of Research and Development |
Cocaine Addiction|Cocaine Dependence
|
January 2011 | Phase 2|Phase 3 |
| NCT03347526 | University of Colorado, Denver|Pediatric Epilepsy Research Foundation|West Therapuetics, Inc |
Infantile Spasm
|
April 19, 2018 | Phase 3 |
| NCT00730522 | Catalyst Pharmaceuticals, Inc. |
Methamphetamine Dependence
|
July 2008 | Phase 2 |
| NCT04321395 | Washington University School of Medicine |
NAFLD|Obesity
|
August 23, 2021 | Phase 2 |
| NCT02849457 | Martina Bebin|National Institute of Neurological Disorders and Stroke (NINDS)|University of Alabama at Birmingham |
Tuberous Sclerosis Complex
|
December 2016 | Phase 2 |
| NCT04987463 | Katarzyna Kotulska|Children´s Memorial Health Institute, Poland |
Tuberous Sclerosis Complex
|
May 7, 2021 | Phase 2|Phase 3 |
| NCT01585207 | Barbara J. Coffey|Icahn School of Medicine at Mount Sinai |
Tourette´s Disorder
|
July 2012 | Phase 1|Phase 2 |
| NCT00626834 | National Institute on Drug Abuse (NIDA) |
Cocaine Addiction
|
February 2008 | Phase 1 |
| NCT01335867 | University of Pennsylvania|National Institute on Drug Abuse (NIDA) |
Alcoholism|Cocaine Dependence
|
April 2011 | Phase 2 |
| NCT00373581 | New York State Psychiatric Institute|Novel Cocaine Pharmacotherapies |
Cocaine Dependence
|
April 2006 | Phase 2 |
| NCT01266291 | University of Pennsylvania|H. Lundbeck A+S |
Complex Partial Seizures
|
August 2010 | Phase 4 |
| NCT02299115 | The Hospital for Sick Children |
Infantile Spasms
|
September 5, 2017 | Phase 3 |
| NCT01413711 | Lundbeck LLC |
Infantile Spasms
|
June 2012 | Phase 4 |
| NCT02220114 | Orphelia Pharma|Institut National de la Santé Et de la Recherche Médicale, France|Hospices Civils de Lyon|National Research Agency, France |
Infantile Spasms
|
May 2014 | Not Applicable |
| NCT03421496 | Benuvia Therapeutics Inc. |
Infantile Spasm
|
September 5, 2018 | Phase 3 |
Solid
Room temperature in continental US; may vary elsewhere.
4°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
H 2 O : 33.33 mg/mL ( 201.24 mM ; Need ultrasonic)
DMSO : 27.5 mg/mL ( 166.04 mM ; Need ultrasonic and warming)
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 6.0379 mL | 30.1896 mL | 60.3792 mL |
| 5 mM | 1.2076 mL | 6.0379 mL | 12.0758 mL |
| 10 mM | 0.6038 mL | 3.0190 mL | 6.0379 mL |
Add each solvent one by one: PBS
Solubility: 10 mg/mL (60.38 mM); Clear solution; Need ultrasonic
Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (15.09 mM); Clear solution
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (15.09 mM); Clear solution